Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Repatha
|
| gptkbp:addresses |
high residual cardiovascular risk
|
| gptkbp:aims_to |
major adverse cardiovascular events
|
| gptkbp:analyzes |
gptkb:evolocumab
|
| gptkbp:applies_to |
patients with atherosclerotic cardiovascular disease
|
| gptkbp:clinical_trial |
PCS K9 inhibitors
|
| gptkbp:completed |
gptkb:2017
|
| gptkbp:conducted |
multiple countries
|
| gptkbp:contributed_to |
understanding of lipid-lowering therapies
|
| gptkbp:depicted_in |
benefits in high-risk populations
reduction in heart attack rates |
| gptkbp:ends_at |
hospitalization for unstable angina
|
| gptkbp:exhibited_at |
significant reduction in LDL levels
|
| gptkbp:fledging_period |
up to 5 years
|
| gptkbp:focuses_on |
cardiovascular outcomes
|
| gptkbp:has |
evolocumab significantly lowers LDL cholesterol
|
| gptkbp:has_impact_on |
gptkb:legislation
cholesterol management guidelines |
| gptkbp:has_influence_on |
clinical practice in cardiology
|
| https://www.w3.org/2000/01/rdf-schema#label |
FOURIER trial
|
| gptkbp:involves |
27,564 participants
patients on statin therapy |
| gptkbp:is_a_center_for |
hundreds of sites
|
| gptkbp:is_associated_with |
improved patient outcomes
reduced stroke rates |
| gptkbp:is_cited_in |
numerous research articles
|
| gptkbp:is_compared_to |
evolocumab to placebo
|
| gptkbp:is_considered |
a landmark study
|
| gptkbp:is_critical_for |
understanding cardiovascular risk factors
|
| gptkbp:is_influential_in |
the development of new drugs
|
| gptkbp:is_part_of |
the ODYSSEY program
the evolution of cardiovascular therapies the evolution of lipid management strategies the ongoing research in cardiovascular medicine |
| gptkbp:is_recognized_by |
its contribution to clinical research.
|
| gptkbp:is_referenced_in |
medical textbooks
|
| gptkbp:is_studied_in |
random assignment of participants
understanding PCS K9 inhibitors |
| gptkbp:launched |
gptkb:2013
|
| gptkbp:led_to |
gptkb:Dr._Steven_Nissen
new treatment protocols |
| gptkbp:measures |
low-density lipoprotein cholesterol
|
| gptkbp:presented_by |
major cardiology conferences
|
| gptkbp:primary_source |
cardiovascular death
|
| gptkbp:provides_information_on |
long-term safety of evolocumab
|
| gptkbp:published_by |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:receives_funding_from |
gptkb:Company
|
| gptkbp:registration |
gptkb:Clinical_Trials.gov
|
| gptkbp:sponsor |
gptkb:Amgen
|
| gptkbp:uses |
randomized controlled trial design
|